Abstract: Composition and methods for treating brain “plaques” and/or “tangles” in a subject wherein the method comprises administration of a therapeutically effective amount of a composition comprising a black currant extract, Uncaria tomentosa extract, and an oolong tea extract.

Abstract: Composition and methods for treating brain “plaques” and/or “tangles” in a subject wherein the method comprises administration of a therapeutically effective amount of a composition comprising a black currant extract, Uncaria tomentosa extract, and an oolong tea extract.

Abstract: A collapsible hanger includes a left arm, a right arm, and a hook. A hinge rotatably holds the left and right arms together. When in expanded state, the left and right arms extend opposite each other. When in collapsed state, the arms are rotated adjacent to each other. The hook is rotatably coupled to one of the arms in a ball and socket arrangement, and rotatable around the ball and socket arrangement between first and second positions. In the first position, the hook curved end is located above a top side of the respective arm. In the second position, the hook curved end is rotated into an opening and recess in the respective arm. A pin holding the hinge together includes a curved end portion overhanging an outer surface of the hinge to form a clasp to hold a collar of a garment.

Abstract: A collapsible hanger includes a left arm, a right arm, and a hook. A hinge rotatably holds the left and right arms together. When in expanded state, the left and right arms extend opposite each other. When in collapsed state, the arms are rotated adjacent to each other. The hook is rotatably coupled to one of the arms, and rotatable between first and second positions. In the first position, the hook curved end is located above a top side of the respective arm. In the second position, the hook curved end is located below the top side of the respective arm and rotated into an opening and recess in the respective arm. Magnets at hinged ends of the arms hold the arms in expanded state. Magnets at distal ends of the arms hold the arms in the collapsed state.

Abstract: A collapsible hanger includes a left arm, a right arm, and a hook. A hinge rotatably holds the left and right arms together. When in expanded state, the left and right arms extend opposite each other. When in collapsed state, the arms are rotated adjacent to each other. The hook is rotatably coupled to one of the arms in a ball and socket arrangement, and rotatable around the ball and socket arrangement between first and second positions. In the first position, the hook curved end is located above a top side of the respective arm. In the second position, the hook curved end is rotated into an opening and recess in the respective arm. A pin holding the hinge together includes a curved end portion overhanging an outer surface of the hinge to form a clasp to hold a collar of a garment.

Abstract: A collapsible hanger includes a left arm, a right arm, and a hook. A hinge rotatably holds the left and right arms together. When in expanded state, the left and right arms extend opposite each other. When in collapsed state, the arms are rotated adjacent to each other. The hook is rotatably coupled to one of the arms, and rotatable between first and second positions. In the first position, the hook curved end is located above a top side of the respective arm. In the second position, the hook curved end is located below the top side of the respective arm and rotated into an opening and recess in the respective arm. Magnets at hinged ends of the arms hold the arms in expanded state. Magnets at distal ends of the arms hold the arms in the collapsed state.

Abstract: Methods for the synthesis, isolation, and purification of procyanidin B2 are disclosed. The synthetic methods utilize epicatechin as a starting material and produce procyanidin B2 in high yields. The isolation methods extract procyanidin B2 from a sample of bark powder from plant matter of the genus Uncaria. The isolated and/or synthesized procyanidin B2 is used to treat amyloid disease, such as Alzheimer's disease and Parkinson's disease as well as improve cognitive performance and increase learning and memory in Alzheimer's patients. Pharmaceutical compositions containing the synthesized and/or isolated procyanidin B2 are also disclosed.

Abstract: Dihydroxyaryl compounds and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of ?-amyloid diseases, such as observed in Alzheimer's disease, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Abstract: Compounds and their pharmaceutically acceptable salts, their synthesis and labeling, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, including A? amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment are provided. Also provided is the use of the disclosed compounds as imaging agents and methods for in vivo imaging and detection of amyloid and synuclein.

Abstract: Methods for treating amyloid disease in a patient wherein the method comprises administration of a therapeutically effective amount of a composition comprising Uncaria tomentosa extract and Grape Seed Extract.

Abstract: Dihydroxyaryl compounds and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of ?-amyloid diseases, such as observed in Alzheimer's disease, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Abstract: Methods for treating amyloid disease in a patient wherein the method comprises administration of a therapeutically effective amount of a composition comprising Uncaria tomentosa extract, Gingko Biloba, Green Tea Extract, Grape Seed Extract and/or Curcumin.

Abstract: Dihydroxyaryl compounds and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of ?-amyloid diseases, such as observed in Alzheimer's disease, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.

Abstract: Substituted n-aryl benzamides, related compounds and their pharmaceutically acceptable salts, their synthesis and labeling, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, including A? amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment are provided. Also provided is the use of the disclosed compounds as imaging agents and methods for in vivo imaging and diagnosis of amyloid and synuclein diseases.

Abstract: Methods for the synthesis, isolation, and purification of procyanidin B2 are disclosed. The synthetic methods utilize epicatechin as a starting material and produce procyanidin B2 in high yields. The isolation methods extract procyanidin B2 from a sample of bark powder from plant matter of the genus Uncaria. The isolated and/or synthesized procyanidin B2 is used to treat amyloid disease, such as Alzheimer's disease and Parkinson's disease as well as improve cognitive performance and increase learning and memory in Alzheimer's patients. Pharmaceutical compositions containing the synthesized and/or isolated procyanidin B2 are also disclosed.

Abstract: A method of treating an amyloid disease, or a disease characterized by alpha-synuclein or NAC fibrillogenesis, in a mammalian subject. The method includes administering to the mammal a therapeutically effective amount of a various disclosed catechins or green tea extract. A pharmaceutical composition comprising a therapeutically effective amount of a catechin and a pharmaceutically acceptable excipient. The therapeutic amount of the catechin or green tea extract is selected for efficacy in treating amyloid, alpha-synuclein or NAC fibrillogenesis in a mammalian subject.

Abstract: Methods for the synthesis, isolation, and purification of procyanidin B2 are disclosed. The synthetic methods utilize epicatechin as a starting material and produce procyanidin B2 in high yields. The isolation methods extract procyanidin B2 from a sample of bark powder from plant matter of the genus Uncaria. The isolated and/or synthesized procyanidin B2 is used to treat amyloid disease, such as Alzheimer's disease and Parkinson's disease as well as improve cognitive performance and increase learning and memory in Alzheimer's patients. Pharmaceutical compositions containing the synthesized and/or isolated procyanidin B2 are also disclosed.

Abstract: A method of induction of amyloid plaques includes immobilizing a quantity of a selected sulfated glycosaminoglycan (SGAG) on a selected medium and adding to the immobilized SGAG on the medium a quantity of dissolved low fibrillar A? 1-40 (LFA?). The LFA? is added preferably in a A?:SGAG w/w ratio of about 1:1. SGAGs are preferably selected from heparin, heparan sulfate, keratan sulfate, dermatan sulfate, chondroitin-4-sulfate and chondroitin-6-sulfate.

Abstract: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of synucleinopathies, such as Parkinson's disease, and the manufacture of medicaments for such treatment.

Abstract: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially A? amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, AA/SAA amyloidosis, such as observed in systemic AA amyloidosis and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment.